A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab

Transplantation

Volumn 96, Issue 9, 2013, Pages 800-806

  Ciancio, Gaetano ^a   Sageshima, Junichiro ^a   Akpinar, Edip ^a   Gaynor, Jeffrey J ^a   Chen, Linda ^a   Zarak, Alberto ^a   Hanson, Lois ^a   Tueros, Lissett ^a   Guerra, Giselle ^a,b   Mattiazzi, Adela ^b   Kupin, Warren ^b   Roth, David ^b   Ricordi, Camillo ^b   Burke III, George W ^a,b  

^a Florida   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Alemtuzumab; Allograft tolerance; Donor derived hematopoietic stem cells; Living related kidney transplantation

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; GANCICLOVIR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PARACETAMOL; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; BK VIRUS INFECTION; BONE PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR STEM CELL INFUSION; FEMALE; GLOMERULOPATHY; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKAPHERESIS; LIVING DONOR; MAINTENANCE THERAPY; MALE; MYCOSIS; NEPHRECTOMY; OPEN STUDY; PATIENT SAFETY; PILOT STUDY; PLASMAPHERESIS; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; STEM CELL TRANSPLANTATION; THERAPY EFFECT; TRANSPLANTATION TOLERANCE; VIRUS ENCEPHALITIS;

EID: 84888132909     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182a0f68c     Document Type: Article

References (30)

1. Monaco AP, Clark AW, Wood ML, et al. Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: Case report of an initial attempt. Surgery 1976; 79: 384
2. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68: 480
3. Barber WH, Mankin JA, Laskow DA, et al. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 1991; 51: 70
4. Burke GW, Ricordi C, Karatzas T, et al. Donor bone marrow infusion in simultaneous pancreas/kidney transplantation with OKT3 induction: Evidence for augmentation of chimerism. Transplant Proc 1997; 29: 1207
5. Ciancio G, Miller J, Garcia-Morales RO, et al. Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation 2001; 71: 827
6. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002; 73: 1386
7. Shapiro R, Jordan ML, Basu A, et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 2003; 238: 520
8. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: Preliminary results. Transplantation 2004; 78: 426
9. Jin Y, Fuller L, Rosen A, et al. Campath-1H does not alter bone marrow cell regulatory function. Hum Immunol 2005; 66: 637
10. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701
11. Bradley JA. Induction of transplant tolerance through mixed hematopoietic chimerism. Am J Transplant 2012; 12: 1073
12. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353
13. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358: 362
14. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012; 4: 124
15. Fontes P, Rao AS, Demetris AJ, et al. Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet 1994; 344: 151
16. Starzl TE, Demetris AJ, Trucco M, et al. Chimerism and donorspecific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation 1993; 55: 1272
17. Starzl TE. Acquired immunologic tolerance: With particular reference to transplantation. Immunol Res 2007; 38: 6
18. Ciancio G, Burke GW, Garcia-Morales R, et al. Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients. Transplantation 2002; 74: 488
19. Cirocco RE, Carreno MR, Mathew JM, et al. FoxP3 mRNA transcripts and regulatory cells in renal transplant recipients 10 years after donor marrow infusion. Transplantation 2007; 83: 1611
20. Mathew JM, Ciancio G, Burke GW, et al. Immune ''tolerance profiles'' in donor bone marrow infused kidney transplant patients using multiple ex vivo functional assays. Hum Immunol 2010; 71: 566
21. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120
22. Ciancio G, Burke GW 3rd. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008; 8: 15
23. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909
24. Macedo C, Walters JT, Orkis EA, et al. Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation 2012; 93: 813
25. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465
26. Valujskikh A, Li XC. Frontiers in nephrology: T cell memory as a barrier to transplant tolerance. J Am Soc Nephrol 2007; 18: 2252
27. Mathew JM, Carreno M, Fuller L, et al. In vitro immunogenicity of cadaver donor bone marrow cells used for the induction of allograft acceptance in clinical transplantation. Transplantation 1999; 68: 1172
28. Knechtle SJ, Pirsch JD, H Fechner JJ, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722
29. Garcia-Morales R, Carreno M, Mathew J, et al. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. J Clin Invest 1997; 99: 1118
30. Suthar K, Vanikar AV, Trivedi HL. Renal transplantation in primary focal segmental glomerulosclerosis using a tolerance induction protocol. Transplant Proc 2008; 40: 1108